Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced its inclusion in a NetworkNewsAudio Audio Press Release highlighting the company's novel approach to treating multiple sclerosis (MS). The audio feature, titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis," accompanies a previously published editorial discussing the growing need for therapies that go beyond symptom management. This announcement comes as the global MS therapeutics market is projected to reach $38.62 billion by 2030, underscoring the significant commercial potential and urgent demand for disease-modifying treatments.
The feature highlights Quantum BioPharma's lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed to target the myelin sheath directly with the goal of preventing, stopping, and potentially reversing its degradation. Myelin degradation is the underlying mechanism of multiple sclerosis, a chronic neurodegenerative disease that affects millions worldwide. Current therapies primarily focus on managing symptoms, but Lucid-MS aims to alter the course of the disease itself. According to the company, the therapy is intended to address the significant unmet need for disease-modifying treatments that can change the trajectory of MS.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), Quantum focuses on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, offering hope for patients who currently have limited options to slow or halt disease progression.
The global MS therapeutics market's projected growth to $38.62 billion by 2030 reflects the rising prevalence of the disease and the increasing demand for effective treatments. For patients, a therapy like Lucid-MS could mean the difference between progressive disability and maintaining quality of life. For the industry, successful development could set a new standard for MS care, potentially shifting the focus from symptom management to disease modification and repair.
Quantum BioPharma also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, further strengthening its position in the neurodegenerative disease space. The company's broader pipeline includes drug candidates for neurodegenerative and metabolic disorders, as well as alcohol misuse, indicating a diversified approach to tackling complex health challenges.
The full press release and audio feature can be accessed at https://nnw.fm/eI6Gv. For the latest news and updates relating to QNTM, visit the company's newsroom at https://nnw.fm/QNTM.
